ABSTRACT-The immunological barrier remains the major obstacle to the widespread use of transplanta tion as a replacement therapy for terminal organ failure. Since the first successful renal transplant, perform ed by Hume et al. (1952), there has been an elusive search for agents that can render the immune mechanism unresponsive to the specific alloantigen stimulus of the engrafted organ, while sparing non-specific host resistance. Immunosuppressive therapies in organ transplantation can be divided into the following four main classes: chemical (pharmaceutical), biological (immunological), physical (radiological) and surgical. Of these, chemical agents (drugs) have continued to play a principal role. The discovery of new immuno suppressive drugs such as corticosteroids, ciclosporin, azathioprine and FK506 have been epoch-making discoveries at each stage in the history of clinical organ transplantation.
Introduction
The success of organ transplantation depends mainly on immunosuppressive therapy. The immunosuppressive methods can be divided into the following four classes: chemical (pharmaceutical), biological (immunological), physical (radiological) and surgical (Table 1) . Of these, chemical agents (drugs) have continued to play a principal role in immunosuppression after transplantation. The rapid increase in number of kidney transplants began with combined use of azathioprine (Az) with corti costeroids in 1963, and the tremendous advances in results of heart and liver transplants were achieved by introduction of ciclosporin (CsA) in the early 1980s. However, the advantages and limitations of currently used immunosuppressive drugs are well-known. The immunosuppressive drugs have various degrees of toxic side effects on vital organs and tissue, and they can in crease susceptibility to infections with microorganisms and the risk of malignancy, since they never suppress transplantation immunity alone. At the present time, two or more immunosuppressive drugs are used in com bination to achieve the maximum therapeutic effects with the minimum toxicity of each. The selection of immuno suppressive drugs used in combination depends on the mechanisms of action of each drug. The most ideal com bination consists of drugs with different effects on the immune system and without overlapping toxicities. In recent years, many new immunosuppressive drugs have been discovered, developed and applied to clinical trials for their use in combination therapy, expecting them to exert complementary and synergistic effects.
Some drugs developed as anti-cancer agents, including Az, methotrexate (MTX) and mizoribine (Mz), were incidentally found to have immunosuppressive activity, whereas the immunosuppressive activity of other drugs such as CsA, tacrolimus (FK506), deoxyspergualin (DSG), mycophenolate mofetil (RS) and rapamycin (Rapa) were detected through screening of the fermen tation products for anti-tumor or anti-microbial antibiotics ( Fig. 1, Table 2 ). These drugs can be classified according to their sites or phases of action for inhibition as follows:
1. Cytokine synthesis (GO phase): CsA, FK506 2. Cytokine action (G1 phase): Rapa 3. DNA synthesis (S phase): Az, RS, Mz 4. Cell maturation (M phase): DSG Thus, most immunosuppressive drugs block T cell func tion, but not all drugs suppress B cells directly. The im mune response to alloantigen is initiated by recognition through binding of T cell receptors, CD4 and CD8 anti gens to MHC class II and class I antigen, respectively, followed by intracellular signalling to activate T cells and then T cell proliferation and differentiation. The recogni tion of alloantigen can not be blocked by chemical agents but is blocked by monoclonal antibodies to surface molecules of T cells.
In this article, the proposed mechanisms of action, side effects and dosages in clinical use of the currently used immunosuppressive drugs including corticosteroids are reviewed. In addi tion, steroids can inhibit killer T cell activity by blocking the production of IL-2 by helper T cells (1). Steroids show both preventive and therapeutic effects on allograft rejec tion, probably due to the above-mentioned effects on T cells, as well as potent antiinflammatory effects due to their inhibitory effects on cyclooxygenase activity, result ing in inhibition of prostaglandin synthesis. Although B cells are resistant to steroids, steroids seem to indirectly inhibit antibody production due to their effects on mac rophages and helper T cells. Thus, steroids show a wider spectrum of effects than other immunosuppressive agents. However, their immunosuppressive effects are generally weak, and their efficacy decreases or is resistant in long term treatment. The experience of transplant physicians plays a major role in their effective and safe use because their immunosuppressive and anti-inflammatory effects cause various side effects on gastrointestinal and meta bolic systems, and there is no well-defined criteria regard ing their optimal doses. In general, steroids are admin istered at a dose of 10-20 mg/kg as methylprednisolone on the day of transplantation.
Doses are tapered there after from 1-2 mg/kg/day to 0.3 mg/kg/day in 3 months and then to 0.15-0.2 mg/kg/day (maintenance doses) in the subsequent 3 months. Upon onset of acute rejection, 500-1,000 mg/day of methylprednisolone is intravenously injected for 2 or 3 days (bolus therapy), and then the dose is gradually reduced, by 50% every 3 days. Az is obtained by substituting the position-6 hydrogen of 6-mercaptopurine with an imidazole ring. Its combined use with steroids was central to the immunosuppressive regimen following kidney transplantation for more than 15 years until 1980. Az affects the S-phase of the cell cycle and shows immunosuppressive effects by inhibiting the synthesis of nucleic acid and is effective for all T cell mediated immune reactions. In large doses, it inhibits B cell functions and antibody production. These effects are useful for preventing rejection, but increase the risk of infections. The disadvantages of Az are bone marrow suppression resulting in leukocytopenia, thrombocyto penia, and anemia and hepatotoxicity, but severe leuko cytopenia can be avoided by careful adjustment of the doses. In clinical use of this drug, it is critical to deter mine the optimal dose; i.e., the dose that results in the maximum immunosuppressive effects with minimum side effects. The optimal dose is generally determined based on blood leukocyte counts. According to our study on the relationship between the doses of Az and renal graft func tion in 104 living related renal transplant recipients, the optimal doses of Az were 2.45 mg/kg/day for the initial 60 days after transplantation and 2.43 mg/kg/day from 61 to 91 days after transplantation (2). The incidence of acute rejection in haploidentical donor kidney transplants with Az therapy was about 60%. Since the development of CsA, Az has become the drug of second choice. However, CsA has some side effects (mentioned in section Mz was developed in Japan as an alternative to Az in the late 1970's. Mz, an imidazole nucleotide, is an anti biotic with a molecular weight of 500 (3). It inhibits nucleic acid synthesis and cell proliferation by blocking the pathway from the xanthine-5 nucleotide to the guanosine-5 nucleotide in purine biosynthesis. It causes less hepatic dysfunction and bone marrow suppression than Az. Since its immunosuppressive effects are not as strong as those of Az, however, it has been mainly used in combination with other immunosuppressive agents. Co administration of CsA with Mz is recommended by some authors who found synergistic effects. This approach is commonly used in patients with hepatic dysfunction caused by drugs or viral hepatitis. Due to its weak im munosuppressive effects, Mz must be administered at doses 2 to 3 times greater than Az in order to obtain comparable efficacy. The major side effects are gastro intestinal disorders and bone marrow suppression, but the latter is less severe than that caused by Az. CsA is a metabolite generated by Tolypocladium infla tum (Gams), a kind of fungus, and is a cyclic peptide with a molecular weight of 1,202 composed of I1 amino acids. Since 5 amino acids are methylated, CsA is extremely hydrophobic. Borel et al. (4) reported in 1977 that it has immunosuppressive effects. CsA was first used clinically by Calne et al. (5) for kidney transplantation and Powles et al. (6) for bone marrow transplantation. This drug has attracted much attention because it has great immuno suppressive effects not only in kidney transplant patients (Table 3) , but in recipients of other organs such as the heart and liver as well. CsA has entirely different mechanisms of action from conventional non-specific immunosuppressive agents such as steroids, Az and cy clophosphamide. The action of CsA is very specific for lymphocytes and its effects are reversible.
Inhibition of immune responses
a) Effects on mixed lymphocyte reaction (MLR) and cell-mediated lympholysis (CML): MLR is an in vitro event that reflects host reactions to grafts. White et al. (7) reported that CsA completely inhibits human MLR at 100 ng/ml and that the presence of CsA from an initial stage is essential for this inhibitory effect. CsA was also found to dose-dependently inhibit the induction of killer T cell activity in CML following MLR. b) Inhibition of cytokine production ( MLR experiments, respectively, that production of IL-2 was decreased in the presence of CsA. In an in vivo study, we confirmed that the IL-2 production by peripheral lymphocytes was decreased markedly in renal transplant patients treated with CsA and was increased at the onset of acute rejection (10). We also found using complemen tary DNA for RNA of IL-2 that the amount of messenger RNA (mRNA) for IL-2 was decreased markedly in renal transplant recipients treated with CsA, indicating that CsA inhibited IL-2 production at a stage preceding mRNA transcription (11). Beside IL-2, CsA has been shown to inhibit the production of various immuno modulators, such as interferon-; (IFN-i), IL-6, macro phage chemotactic factor (MCF) and macrophage acti vating factor (MAF). Abbud-Filho et al. (12) reported, based on their findings obtained in the rat heart trans plant model, that while the production of IL-1 and IL-2 was inhibited by CsA, IL-3 activity was enhanced, and suggested that IL-3 might be involved in the growth and differentiation of suppresser T cells.
c) Effects on suppressor T cells: Wang et al. (13) and Hess et al. (14) reported that specific and non-specific suppressor T cell activities were not affected by CsA at 1 ig/ml or lower concentrations, although the activation of killer T cells was inhibited in MLR. DosReis et al. (15) showed that suppressor T cells were induced in the MLR of guinea pigs in the presence of CsA and that these sup pressor T cells produced antigen non-specific suppressor factor (TsF). We confirmed in an in vivo study that sup pressor T cells that inhibit the induction of killer T cells against alloantigens were present in mouse splenic cells treated with alloantigen and CsA and a humoral factor (TsF) mediated their activity (16). The fact that suppres sor T cells are induced despite marked decreases of IL-2 production due to CsA administration suggests that their growth and differentiation do not entirely depend on IL-2 and that other mechanisms are involved in these process es. This hypothesis is supported by a study by Hess et al.
(17), who found that the MLR supernatant containing CsA specifically enhanced suppressor T cell activity, an tigen-specific OKT8+ suppressor T cell activity, despite the absence of IL-2, IL-1 (a and ,5) or IFN-7 activity, and the culture supernatant induced the proliferation of T cell clones stimulated by MLR.
d) Mechanisms of action on the molecular level: Merker et al. (18) discovered a substance of 16 kD that is bound to CsA in the cytoplasm, named it cyclophyllin and proposed a hypothesis that CsA exerts its immuno suppressive effects by binding cyclophyllin and blocking the influx of calcium necessary for lymphocyte acti vation into the cytoplasm. A recent study showed that CsA receptors are peptidylprolineisomerase (PPlase), and its enzymatic activity is lost when CsA is bound to cyclophyllin or PPlase (19). In lymphocytes, calcineurin which is a protein phosphatase and requires calcium for its activation, has a key role in the calcium-dependent pathway to the IL-2 gene. The CsA-cyclophyllin complex binds calcineurin. Calcineurin involved in this supercom plex can no longer be activated by calcium, and thereby signal progression to the IL-2 gene is blocked (20). CsA is administered either orally or intravenously. In travenous administration is conducted over a period of at least 4 hr every 12 hr, while oral administration is carried out once or twice a day. When administered orally, about 40% of the dose is absorbed through the small intestine, while a part of it is transferred into the bile duct and ab sorbed from the small intestine. CsA is excreted mainly into bile and partly into urine. Blood concentrations peak 3 to 4 hr after oral administration and decrease rapidly thereafter. In general, concentrations in whole blood are measured by radioimmunoassay or fluorescence polariza tion immunoassay using monoclonal antibodies immedi ately before oral administration (trough level), and the dose is adjusted to 100-200 ng/ml in the case of renal transplantation.
There are many reports of drug inter actions with CsA. Hepatic metabolism of cytochrome P450-dependent mono-oxygenases is the primary means of CsA elimination. Therefore, co-administration of any drug with the ability to alter the activity of the mono-oxygenases has the potential to affect CsA blood levels. The inhibition of cytochrome P450 could cause decreased CsA metabolism, leading to high blood levels of CsA, whereas its induction could result in increased CsA metabolism resulting in low blood levels of CsA. Thus, the usual consequence of drug interactions with CsA is either a decrease in immunosuppression or the ap pearance of CsA toxicity. A list of drug interactions with CsA is given in 
Side effects and complications
The major side effect of CsA is nephrotoxicity. Impair ment of renal function due to nephrotoxicity has a serious impact on the prognosis of renal grafts. It is important to differentiate nephrotoxicity from acute rejection at an early stage after transplantation and from chronic rejec tion at a later stage. In addition to clinical findings in cluding changes in renal function test, amounts of urinary protein and fibrin-fibrinogen degradation products pro vide useful information for differentiating nephrotoxicity from acute rejection, but time-course changes in blood CsA concentrations, in particular the trough level, are critical for making this differentiation. Acute nephro toxicity at an early stage after transplantation is closely correlated with blood trough levels of CsA and is revers ible with dose reduction. Chronic nephrotoxicity and microangiopathy, which are irreversible and can lead to interstitial fibrosis, are thought to be induced by high initial doses of CsA or repetitive acute nephrotoxicity. Typical histological changes due to nephrotoxicity in clude vacuolation, calcification and lipofuscinosis of renal tubular epithelial cells. Recently, CsA with drastic reduction in initial dose is preferably combined with Az or Mz to prevent acute nephrotoxicity (Ref. 21, Fig. 3 ), especially in case of cadaveric kidney transplant with ischemic damage. Although the precise pathogenesis of CsA nephrotoxicity remains unclear, tubular toxicity theo ry and vasoconstrictive theory in relation to activation of the renin-angiotensin system, inhibition of prostaglan din or stimulation of the sympathetic nervous system are postulated. Hepatotoxicity represented by slightly ele vated serum bilirubin or transaminases levels is frequent during the early posttransplant period and is self-limited with dose reduction in most cases. The occurrence of hypertension and hyperkalemia may be related to CsA nephrotoxicity. We first proposed the toxic effect of CsA on the pancreas from our results that 32 (30.5%) of the 105 patients treated with CsA requird insulin therapy, compared to only 38 (21.1010) of the 180 patients treated with AZ, and acute pancreatitis occurred in 4 of 105 patients treated with CsA.
The incidence of infections, in particular serious bac terial pneumonia and sepsis, has decreased since the in troduction of CsA, while the incidence of CMV infection (22) and Pneumocystis carinii pneumonia (23) has been reported to be increased. To prevent these side effects or complications caused by CsA, careful monitoring of CsA blood levels are needed. However, the absorption, metabolism and excretion of CsA are variable within an individual, as well as among individuals, influenced by hepatic function, intestinal condition and/or diet intake. For more stable pharmacokinetics and better bio availability of CsA, its new microemulsion formulation, NeoralU' has been introduced and a multi-center clinical trial on this preparation is starting in Japan. 6. Tacrolimus  (FK506) FK506, a metabolite produced by Streptomyces tsukubaensis, microorganism belonging to the actino myces family, is a macrolide with a molecular weight of 822 (24). Although the molecular structure is quite different from CsA, which is a cyclic peptide, the mode of its immunosuppressive action is similar to that of CsA. FK506 also affects helper T cells and inhibits the differen tiation of cytotoxic T cells by inhibiting the production of IL-2 and expression of IL-2 receptors. FK506 binds to another member of the cytoplasmic protein family (immunophyllin), FK binding protein (FKBP), as CsA binds to cyclophylin. The FK506-FKBP complex binds calcineurin to form a super-complex in which calcineurin can not be activated by calcium. Thus, the signal trans duction to the IL-2 gene and other cytokines is blocked. FK506 is 10 to 100 times more potent than CsA in in hibiting alloreactive T cell proliferation, B cell activation and the production of other cytokines such as IL-3, IL-4, IFN-r and G-CSF, although it does not inhibit the second ary proliferation of activated T cells in response to IL-2. FK506 shows considerable variation in its pharmaco kinetic profile among individuals. Since it is almost com pletely metabolized in the liver, hepatic dysfunction causes its accumulation in the body and elevated blood levels of FK506. In blood, FK506 is sequestered by erythrocytes and its plasma concentrations are influenced by the hematocrit, plasma protein levels and temperature (25). Therefore, levels of FK506 in whole blood must be measured instead of those in plasma or serum. In the early phase II clinical trials in Japan (25), FK506 was orally administered at a dose of 0.15 mg/kg every 12 hr starting 2 days before transplantation, followed by con tinuous intravenous injection at 0.1 mg/kg/24 hr for 3 days from the day of transplantation and thereafter oral administration of 0.15 mg/kg twice a day (Fig. 4) . Since the side effects of FK506 are related to blood concentra tions as in the case of CsA, the doses have to be adjusted according to blood concentrations determined by ELISA. The target blood concentrations after transplantation are set at 20 ng/ml until 10 days, 15 ng/ml until 90 days and 10 ng/ml thereafter. Prednisolone is used as a concurrent drug. However, according to a report from Pittsburgh (26), the use of FK506 made it possible to completely withdraw steroids in 60010 of kidney transplant patients. The steroid-sparing effects of FK506 may prove to be of particular value in children. Compared with CsA as a primary immunosuppressant, FK506 showed comparable or greater patient and graft survival rates in kidney and liver transplantation (Table 5 ). In a late-phase II clinical trial in Japan on kidney transplantation (27), a graft survival rate of 95.9% at 3 years after transplantation was achieved with a 36% incidence of acute rejection. In liver transplant patients treated with FK506, the graft survival rate at one year exceeded 80010 (28). There was no significant difference in patient or graft survival rate between FK506 and CsA therapy, but the incidence of refractory rejection was significantly less in patients treat ed with FK506 (29). FK506 has been found to reverse ad vanced cellular rejection; in kidney transplantation, 76010 of patients who experienced refractory rejection had remission when CsA was replaced with FK506 (30). The major side effects of FK506 are very similar to those of CsA, possibly because of the similarity of modes of ac tion, and include nephrotoxicity, neurotoxicity, diabeto genicity, gastrointestinal symptoms and so on. FK506 has a direct glomeruloconstrictive effect that leads to reduced renal perfusion and glomerular flow. Associated with the nephrotoxicity, hyperkalaemia and hypertension can oc cur, but the former is more and the latter is less frequent in FK506 therapy, as compared with CsA. Neurological side effects can be categorized as major (seizures, aphasia, function predominantly, includ ing inhibition of oxidative metabolism, lysosomal en zyme synthesis, IL-1 production and cell surface expres sion of MHC II antigens. The inhibitory effect of DSG on T cell activation is abolished by IFN-1 and partly by IL-2, suggesting that suppressive mechanism of DSG may be mediated by the inability of lymphocytes to produce . DSG also affects B cells directly and inhibits antibody production. For this reason, DSG is co-admin istered with other immunosuppressive agents in A130 incompatible kidney transplantation. DSG has been shown to reverse ongoing rejection in patients and so can be used for rescue of acute rejection (33). DSG is administered at 3-5 mg/kg/day for 7 to 10 days by i.v. drip infusion. Major side effects include bone marrow suppression, and gastrointestinal discomfort. However, since the myelotoxic effects are cytostatic, bone marrow elements regenerate rapidly after the drug is withdrawn.
8. RS-61443 (mycophenolate mofetil, RS) RS is a prodrug of mycophenolic acid (MPA) that is a fermentation product of several Penicillium products. GTP is essential for the synthesis of protein and nucleic acid and for various enzymatic reactions. Inosine 5' monophosphate dehydrogenase (IMPDH) is a rate-limit ing enzyme necessary for the biosynthesis of GTP. Therefore, an increase of IMPDH activity and GTP production is necessary for the proliferation of lympho cytes. RS, a morpholinoethyl ester of MPA, is an inhibi tor of IMPDH, and selectively decreases intracellular GTP and inhibits purine biosynthesis, thereby inhibiting i) the differentiation and growth of T cells and ii) anti body production by B cells. It has been reported that RS not only prevents but reverses rejection of vascularized allografts in both small and large animals, and it has at least an additive effect without any increased toxicity when used in combination with CsA (34, 35) . RS seems to be a promising alternative to Az for clinical use, because it has no toxic effect on the kidney, liver and bonemarrow and causes no increased susceptibility to infections at a dose of 40 mg/kg or more. In humans, RS combined with CsA and steroids decreased the incidence of rejection to 17%Io in comparison with 60% in the absence of RS and moreover could reverse ongoing rejection in the majority of recipients even when high-dose steroids and OKT3 were ineffective (36). A phase II study of RS for dose finding (1,000 to 4,000 mg/day) in Japan has demon strated that the optimal dose is 3,000 mg/day considering the incidence of rejection and side effects (37).
Rapa, a compound with a molecular weight of 914 pro duced by the actinomyces Streptomyces hygroscopicus, was reported for the first time in 1975 as a compound with potent inhibitory activity against Candida albicans (38). The subsequent studies in rats showed that it pre vents experimental allergic encephalomyelitis and ad juvant arthritis and inhibits the production of antibodies (39), suggesting that it might suppress transplant immu nity. Rapa is a macrolide antibiotic like FK506 and has a chemical structure similar to FK506 but acts at a differ ent site. Although Rapa also binds cytoplasmic im munophyllin, FKBP, it fails to inhibit calcineurin (20), because the Rapa-FKBP complex does not bind calcineu rin and does not block its activity or GO to G 1 progres sion, resulting in preservation of signal transduction to the IL-2 gene. The failure to form a supercomplex in Rapa is reported to be caused by the difference of FKBPs for the binding (40). Rapa inhibits the 1L2-IL2 receptor interaction without affecting the production of IL-2 (41). T cell growth induced by IL-2 and IL-4 is only slightly inhibited by FK506 and CsA, but is effectively inhibited by Rapa (39). These findings suggest that unlike FK506 and CsA, Rapa affects T-cell activation by lymphokines at a late stage. While FK506 and CsA affect T-cell activa tion at an early stage and inhibit the production of lym phokines necessary for T-cell activation, Rapa exerts its immunosuppressive effects by inhibiting reactions to these lymphokines. Based on these modes of action, Rapa is expected to inhibit alloreactive cells which are resistant to FK506 or CsA. In fact, the mutually synergistic effect of low doses of Rapa and CsA has been reported in a rat cardiac allograft model (42). Although Rapa and FK506 are mutually antagonists with respect to T cell activation, Morris et al. have reported that this combination acts synergistically to prolong mouse cardiac allograft survival (43). Rapa has been shown to have toxic side effects on the kidney, gastrointestinal system and central nervous system and to be diabetogenic in animal studies. The early phase of the clinical trial of Rapa in combination with CsA and steroids has just started in the United States to find the pharmacokinetic behavior and correlation be tween the trough levels and the occurrence of acute rejec tion or side effects.
Conclusion
Now a variety of prophylactic and therapeutic modal ities are available for controlling of allograft rejection, but there is no single panacea. By proper combined use of these immunosuppressants acting at different sites, more specific suppression of transplantation immunity has been achieved without compromising the host's other im mune responses. In reality, however, a rejection crisis can not completely be prevented or reversed, and a lowered quality of life or even death occurs due to immunosup pression. The final goal of clinical transplantation is to induce allotolerance, in which the graft survives without immunosuppression.
Clinically, there are some allograft recipients having a functioning graft without any im munosuppressive drug, showing tolerance to alloanti gens. In parallel with the development of new immuno suppressive drugs with more specificity and less toxicity, immunological procedures for induction of allotoler ance remain to be established.
